Twenty years of science, twenty years of regulation, one peptide

What the regulatory record actually says

This page follows the scientific and regulatory history of CJC-1295 in order, from the 2005 lab paper that identified it to the December 2024 FDA advisory committee vote. The core facts: three published studies carry most of the scientific weight — Jetté 2005 in rats, Teichman 2006 in healthy adults, Alba 2006 in mice. A Phase 2 trial in HIV patients was halted in 2006 after a participant died; independent review attributed the death to pre-existing heart disease, not to the compound, but development never restarted. In 2024, FDA reviewed it at the Pharmacy Compounding Advisory Committee and voted against allowing it in compounded preparations. CJC-1295 is not a drug that was rejected after completing trials — it is a research chemical that never completed the trials. That gap is what every statute and regulation touching it is reading.

The science, in three studies

The published scientific record on CJC-1295 is small. Three papers carry most of the weight, and the regulatory documents return to them repeatedly.

In 2005, Jetté and colleagues at ConjuChem identified CJC-1295 as a long-lasting GRF analog. Their work in rats showed that hGRF(1-29)-albumin bioconjugates activated the GRF receptor on the anterior pituitary, with CJC-1295 producing a four-fold increase in GH area-under-the-curve over two hours and remaining detectable in circulation beyond 72 hours ^[1]. The four amino acid substitutions in the modified GRF(1-29) backbone — D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27 — extend the in-vivo half-life of the non-DAC peptide from roughly 7 minutes (native GHRH) to approximately 30 minutes; the maleimide tether to albumin Cys34 then pushes the long-acting variant into the day-scale range ^[9].

In 2006, Teichman and colleagues published the only Phase 1 PK/PD trial in healthy adults. Subcutaneous CJC-1295 at 30 to 250 μg/kg produced dose-dependent increases in mean plasma GH of 2- to 10-fold for at least 6 days and mean IGF-I of 1.5- to 3-fold for 9 to 11 days after a single injection; multiple-dose IGF-1 elevation was sustained up to 28 days, and the estimated plasma half-life of the parent compound was 5.8 to 8.1 days ^[2][3]. A companion analysis by Ionescu and Frohman demonstrated that pulsatile GH secretion was preserved under continuous CJC-1295 stimulation — a pharmacologically distinctive profile compared to exogenous recombinant GH, where the pulse architecture is overwritten ^[5].

In 2006, Alba and colleagues showed in GHRH-knockout mice that once-daily subcutaneous CJC-1295 normalized linear growth and body weight; dosing at 48- or 72-hour intervals yielded partial restoration; treatment increased pituitary somatotroph proliferation and GH mRNA ^[4]. A 2009 proteomic substudy in 11 healthy young men identified five differentially expressed serum proteins one week after a single CJC-1295 injection, with the immunoglobulin/albumin fragment spot correlating linearly with IGF-1 levels ^[6].

That is the published scientific record. The Phase 2 trial in HIV-associated visceral adiposity (NCT00267527, n=192) enrolled but did not publish primary endpoints, having been terminated in October 2006 after a participant death from acute coronary event approximately two hours after the eleventh weekly dose. Independent review attributed the event to pre-existing undiagnosed coronary artery disease and judged it unrelated to study drug, but the program was halted and never restarted ^[7]. No further sponsor-funded clinical development has occurred.

The regulatory chronology

The current regulatory posture is the product of a specific sequence of administrative actions, most of them concentrated in 2023 and 2024.

2006. Phase 2 trial NCT00267527 terminated; no NDA filed; no peer-reviewed primary endpoint publication ^[7]. ConjuChem's sponsor-funded development program ends.

2010. A peptide pharmaceutical preparation seized by an anti-doping laboratory was identified as CJC-1295 via LC-HRMS/MS, confirming illicit availability of the compound to athletes outside any approved regulatory channel and prompting the first wave of validated doping-control methods ^[8].

2023. FDA places CJC-1295 in Category 2 of the interim 503A bulks list — significant safety risks identified, compounding not permitted under interim enforcement discretion.

September 20, 2024. FDA announces removal of five peptide bulk drug substances — AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate — from Category 2 of the interim 503A bulks list, effective September 27, 2024, following the nominators' withdrawal of the substances' nominations. The agency simultaneously places CJC-1295, in five chemically distinct bulk substance forms (free base, acetate, DAC free base, DAC acetate, DAC trifluoroacetate), on the agenda for full PCAC re-review at the December 4, 2024 meeting ^[12].

December 4, 2024. At the PCAC meeting, FDA recommends that none of the five CJC-1295 forms be included on the Section 503A bulks list. The agency cites nonclinical findings of reduced food and water intake, softer stools, decreased activity, vomiting, reduced hemoglobin, increased cholesterol, injection-site inflammation and necrosis, and DNA damage in pituitary cells; the unresolved cardiac signal from the 2006 trial termination; and unaddressed immunogenicity concerns of compounded preparations. PCAC votes in alignment with FDA's recommendation against inclusion ^[13].

Late 2024. FDA's Warning Letter campaign expressly targets vendors marketing peptides — CJC-1295 named among them — as for research use only while promoting human use. The agency treats objective evidence of intended use (vendor copy, promotional claims, customer base, dose-form presentation) as overriding the disclaimer language under its intended-use doctrine ^[15][20].

2025. The WADA Prohibited List continues to list CJC-1295 under Section S2.2.4 (Growth Hormone Releasing Factors) — prohibited at all times under strict liability ^[11]. A nano-LC quadrupole/orbitrap mass spectrometry method validated in 2024 enables routine detection of CJC-1295 and related GHRH synthetic analogs in athlete urine at sub-ng/mL concentrations ^[10].

Pathways foreclosed, pathways still open

It is worth being precise about which lawful pathways for U.S. distribution of CJC-1295 are currently foreclosed and which (very few) remain.

Approved-drug pathway. Closed. No NDA, BLA, or ANDA has ever been filed. Under 21 U.S.C. § 355(a), no person may introduce a new drug into interstate commerce unless an FDA-approved application is in effect. CJC-1295 has never had one.

503A traditional pharmacy compounding. Closed. There are three statutory routes to lawful 503A compounding of a bulk substance: (1) the substance is a component of an FDA-approved drug; (2) the substance has a USP/NF monograph; or (3) the substance appears on the FDA 503A bulks list. CJC-1295 satisfies none of the three ^[13].

503B outsourcing-facility manufacturing. Closed. CJC-1295 is not on the 503B bulks list.

DSHEA / dietary supplement pathway. Closed. Because CJC-1295 was the subject of substantial public clinical investigation as a new drug (Teichman 2006; NCT00267527), it is excluded from the definition of a dietary supplement under 21 U.S.C. § 321(ff)(3)(B) ^[19]. Supplement marketing of CJC-1295 is treated by FDA as marketing of an unapproved new drug.

Research use in a properly conducted bench-science context. Open in principle but circumscribed in practice. Research use only is a meaningful regulatory category; what FDA does not accept is the use of that phrase as a shield over conduct whose objective intended use is human administration ^[15]. The agency's intended-use doctrine looks at vendor marketing, promotional claims, customer base, and dose-form presentation to determine the actual regulatory status of the product, not the disclaimer that travels with it.

Import. Constrained under FDCA Section 801(a). FDA may detain and refuse admission to any drug appearing to be adulterated, misbranded, or otherwise in violation of the Act; CJC-1295 shipments are covered by Import Alerts 66-41 and 99-32 ^[18].

The practical upshot is that there is no lawful U.S. commercial pathway for CJC-1295 as a human-administered product today. The lawful pathways for the compound are: properly conducted bench science with documented research use, and academic study of the underlying biology. Everything else sits in a zone where FDA, state pharmacy boards, WADA, the NCAA, and DoD all have something to say.

Why the cardiac-event question still matters

The 2006 Phase 2 trial terminated after a participant died from an acute coronary event roughly two hours after the eleventh weekly dose. The independent review at the time judged the event unrelated to study drug and attributed it to pre-existing undiagnosed coronary artery disease ^[7]. That judgment ended the trial. It did not end the regulatory conversation about it.

FDA's December 2024 PCAC briefing returned to the event explicitly, listing it among the unresolved safety signals weighing against inclusion of CJC-1295 on the 503A bulks list ^[13]. Combined with the agency's catalog of nonclinical findings — DNA damage in pituitary cells, injection-site inflammation and necrosis, reduced food and water intake, decreased activity, vomiting, reduced hemoglobin, increased cholesterol — the cardiac signal contributed to the recommendation against inclusion that PCAC then ratified.

The substantive point is that an adjudicated unrelated finding inside a small terminated trial is not the same thing as an adjudicated safe finding in a completed development program. CJC-1295 never finished its Phase 2 program, never began a Phase 3 program, and has never had its safety profile characterized at the scale required for marketing approval. That gap is part of what the 2024 PCAC vote was reading.